The selective PPARD agonist seladelpar reduced total bile acids in the liver and serum, and reduced ethanol-induced liver disease in mice89 PPARD activation by selective ligands also improved intestinal barrier function, supporting that bile acid metabolism and gut-liver axis are therapeutic targets for ALD treatment by PPARD agonists.90 Here, PPARD is linked to liver disorder.